Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to acquire up to $700 million in BNB cryptocurrency to enhance its balance sheet. This decision follows the recent peak in BNB's value at $808. To finance this initiative, Windtree is raising $520 million primarily through a $500 million equity line of credit and a $20 million stock purchase agreement with Build and Build Corp. The company's CEO, Jed Latkin, emphasized the importance of securing additional funds for purchasing more BNB, pending stockholder approval. BNB, the fifth-largest digital currency, currently holds a market cap of $106.9 billion. This move is reflective of a broader trend where public companies are diversifying their treasury assets beyond Bitcoin. Other firms, including Nano Labs, have also announced significant plans to invest in BNB, signaling an increasing institutional interest in cryptocurrency as a financial asset. Windtree's stock has seen significant gains over the past month, despite a slight dip following this announcement.

Source đź”—